Company profile
Marker Therapeutics, Inc.
NASDAQ:MRKRBiotechnology: Pharmaceutical Preparations
Drug pipeline (2)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| ZEDENOLEUCEL | phase2 | — | 1 | terminated |
| Neldaleucel | phase1 | — | 1 | active |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (6)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04511130 | phase2 | terminated | 2020-10-14 | 2024-03-01 | Marker Therapeutics, Inc. | Efficacy of MT-401 in Patients With AML Following Stem Cell Transplant |
| NCT02978222 | phase2 | terminated | 2017-07-20 | 2020-01-15 | Marker Therapeutics, Inc. | Folate Receptor Alpha Peptide Vaccine With GM-CSF Versus GM-CSF Alone in Patients With Platinum Sensitive Ovarian Cancer |
| NCT02593227 | phase2 | completed | 2016-04-01 | 2021-07-15 | Marker Therapeutics, Inc. | Folate Receptor Alpha Peptide Vaccine With GM-CSF in Patients With Triple Negative Breast Cancer |
| NCT06549751 | phase1 | not_yet_recruiting | 2026-07-16 | 2028-07-16 | Marker Therapeutics, Inc. | MT-601 Administered To Patients With Locally Advanced Unresectable or Metastatic Pancreatic Cancer |
| NCT05798897 | phase1 | recruiting | 2023-01-02 | 2028-02-28 | Marker Therapeutics, Inc. | Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma |
FDA applications (0)
No records yet.